Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Reduced membranous MET expression is linked to bladder cancer progression.

Kluth M, Reynolds K, Rink M, Chun F, Dahlem R, Fisch M, Höppner W, Wagner W, Doh O, Terracciano L, Simon R, Sauter G, Minner S.

Cancer Genet. 2014 Apr;207(4):147-52. doi: 10.1016/j.cancergen.2014.03.008. Epub 2014 Mar 22.

PMID:
24853099
2.

Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer.

Minner S, De Silva C, Rink M, Dahlem R, Chun F, Fisch M, Höppner W, Wagner W, Bokemeyer C, Terracciano L, Simon R, Sauter G, Wilczak W.

Pathology. 2012 Aug;44(5):448-52. doi: 10.1097/PAT.0b013e32835576ee.

PMID:
22772340
3.

Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.

Chen PC, Yu HJ, Chang YH, Pan CC.

J Clin Pathol. 2013 Feb;66(2):113-9. doi: 10.1136/jclinpath-2012-200944. Epub 2012 Oct 19.

PMID:
23087329
4.

High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer.

Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knönagel H, Rist M, Wilber K, Anabitarte M, Hering F, Hardmeier T, Schönenberger A, Flury R, Jäger P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Kallioniemi OP, Sauter G.

Am J Pathol. 2000 Sep;157(3):787-94.

5.

Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient.

Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O.

Mod Pathol. 2011 Aug;24(8):1146-55. doi: 10.1038/modpathol.2011.70. Epub 2011 Apr 8.

6.

High-throughput tissue microarray analysis of CMYC amplificationin urinary bladder cancer.

Zaharieva B, Simon R, Ruiz C, Oeggerli M, Mihatsch MJ, Gasser T, Sauter G, Toncheva D.

Int J Cancer. 2005 Dec 20;117(6):952-6.

7.

Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy.

Denzinger S, Stoehr R, Schwarz S, Eichenseher N, Brockhoff G, Obermann EC, Knuechel R, Blaszyk H, Hartmann A, Wild PJ.

Int J Oncol. 2007 Oct;31(4):793-802.

PMID:
17786310
8.

Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.

Wild PJ, Herr A, Wissmann C, Stoehr R, Rosenthal A, Zaak D, Simon R, Knuechel R, Pilarsky C, Hartmann A.

Clin Cancer Res. 2005 Jun 15;11(12):4415-29.

9.

TRIO amplification and abundant mRNA expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer.

Zheng M, Simon R, Mirlacher M, Maurer R, Gasser T, Forster T, Diener PA, Mihatsch MJ, Sauter G, Schraml P.

Am J Pathol. 2004 Jul;165(1):63-9.

11.

Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.

Bertz S, Otto W, Denzinger S, Wieland WF, Burger M, Stöhr R, Link S, Hofstädter F, Hartmann A.

Eur Urol. 2014 Jan;65(1):218-26. doi: 10.1016/j.eururo.2012.05.033. Epub 2012 May 19.

PMID:
22633802
12.

Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression.

Hagikura M, Murakumo Y, Hasegawa M, Jijiwa M, Hagiwara S, Mii S, Hagikura S, Matsukawa Y, Yoshino Y, Hattori R, Wakai K, Nakamura S, Gotoh M, Takahashi M.

Pathol Int. 2010 Nov;60(11):735-43. doi: 10.1111/j.1440-1827.2010.02592.x. Epub 2010 Oct 6.

PMID:
20946523
13.

High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer.

Wild PJ, Kunz-Schughart LA, Stoehr R, Burger M, Blaszyk H, Simon R, Gasser T, Mihatsch M, Sauter G, Hartmann A.

Int J Oncol. 2005 Aug;27(2):385-91.

PMID:
16010419
14.

Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma.

Liang PI, Wu LC, Sheu JJ, Wu TF, Shen KH, Wang YH, Wu WR, Shiue YL, Huang HY, Hsu HP, Chen YH, Chen LT, Li CF, Liao AC.

J Clin Pathol. 2012 Sep;65(9):802-7. doi: 10.1136/jclinpath-2012-200897. Epub 2012 Jun 9.

PMID:
22685262
15.

Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.

Eltze E, Wild PJ, Wülfing C, Zwarthoff EC, Burger M, Stoehr R, Korsching E, Hartmann A.

Eur Urol. 2009 Nov;56(5):837-45. doi: 10.1016/j.eururo.2008.10.003. Epub 2008 Oct 11.

PMID:
18945538
16.

Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer.

Yamamoto Y, Matsuyama H, Furuya T, Oga A, Yoshihiro S, Okuda M, Kawauchi S, Sasaki K, Naito K.

Clin Cancer Res. 2004 Oct 1;10(19):6449-55.

17.

Decreased expression of KAI1 metastasis suppressor gene is a recurrence predictor in primary pTa and pT1 urothelial bladder carcinoma.

Su JS, Arima K, Hasegawa M, Franco OE, Umeda Y, Yanagawa M, Sugimura Y, Kawamura J.

Int J Urol. 2004 Feb;11(2):74-82.

18.

Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin.

Miyata Y, Sagara Y, Kanda S, Hayashi T, Kanetake H.

Hum Pathol. 2009 Apr;40(4):496-504. doi: 10.1016/j.humpath.2008.09.011. Epub 2009 Jan 3.

PMID:
19121849
19.

Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.

Mhawech-Fauceglia P, Alvarez V, Fischer G, Beck A, Herrmann FR.

Am J Clin Pathol. 2008 Jun;129(6):918-23. doi: 10.1309/D81QMXPMC3QHT57Y.

PMID:
18480009
20.

PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer.

Cordes I, Kluth M, Zygis D, Rink M, Chun F, Eichelberg C, Dahlem R, Fisch M, Höppner W, Wagner W, Doh O, Terracciano L, Simon R, Wilczak W, Sauter G, Minner S.

Histopathology. 2013 Nov;63(5):670-7. doi: 10.1111/his.12209. Epub 2013 Sep 5.

PMID:
24004025

Supplemental Content

Support Center